News
See all news
16 June 2021
COVID-19
UPDATE ! COVID-19: Biological parameters
COVID-19 – (SARS-CoV-2) – screening for S gene By RT-PCR
From the 14th of June 2021, Eurofins Biomnis laboratory offers a screening test for the 3 significant mutations E484K, E484Q and L452R, to be performed in case of a positive test
The evolution of the distribution of the different strains of SARS-CoV-2 and the emergence of new variants of concern (VOC) or of interest (VOI) leads to the evolution of the targets of the screening tests
Screening for anti-S or anti-RBD antibodies (SARS-CoV-2 virus)
Humoral immunity developed from contact with the SARS-CoV-2 virus (post-disease) takes the form of production, by B lymphocytes, of antibodies targeted against the spike (S) and nucleocapsid (N) antigens of the virus: with the appearance of anti-N, anti-S and, more specifically, anti-S1 and anti-RBD type antibodies.
Thus, screening for anti-S or anti-RBD antibodies can be used to search for the presence of humoral immune markers after a Covid infection (or signal a previous contact if diagnosis could not be made), as they seem to persist for longer than anti-N antibodies.
Furthermore, anti-S or RBD antibodies can also be used post-vaccination.
From 1 April 2021, Eurofins Biomnis will be able to perform a “Screening for anti-S or anti-RBD antibodies”
- Analysis code: SRBD
- Sample: Minimum 500 microlitres of serum
- Transport temperature: refrigerated
- Price: Contact the International Division
- When requesting the test, please state: “Assay of anti-S or anti-RBD antibodies”
COVID 19 / Influenza virus A and B – panel – direct diagnosis – PCR
This testing allows the detection of two viruses : Influenza A/ B and SARS-CoV-2 It is carried out by multiplex RT-PCR on a nasopharyngeal swab.
COVID-19 (SARS-CoV-2) – direct diagnosis – PCR
This analysis allows the diagnosis of COVID-19 (SARS-CoV-2) infection. It is based on the detection of SARS-CoV-2 RNA by a real-time RT-PCR technique, in particular via a nasopharyngeal swab.
COVID-19 (SARS-CoV-2) – serology total Ig
This analysis allows the diagnosis of COVID-19 (SARS-CoV-2) infection. Specifically, it is used to determine whether a person has produced antibodies in response to an infection with the virus.
The analysis is based on the detection and quantification of SARS-CoV-2 specific antibodies using a blood sample
